A Surge of Catalysts and Volatility for ImmunityBio
Published on 01/28/2026 at 06:45 | Redaktion boerse-global.de
ImmunityBio has entered 2026 with significant momentum, propelled by a confluence of fresh clinical data, key regulatory communications, and international approvals. This flurry of activity has been mirrored by dramatic swings in the company’s share price, which experienced a powerful rally followed by a notable pullback. The interplay between scientific progress and market turbulence is now a central theme for investors.
The accumulation of clinical and regulatory news in January triggered extraordinary price action for ImmunityBio shares. Despite a recent weekly correction of approximately 14%, the stock remains up nearly 195% year-to-date, following a 30-day surge of around 192%. Over a twelve-month period, the gain exceeds 100%.
Closing recently at $5.95, the equity trades Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
